Therefore, a phase I/II clinical trial using CD8+NKT-like cells to treat patients with advanced melanoma is now conducted in the Beijing Cancer Hospital (NCT02619058) to further explore their antitumor effects in the clinic. This evidence concerns the gene CD8A and melanoma.